DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Change in Account Payables came in at $1.8 million in Q1 2026, up 220.63% year-on-year from $567000.0 in Q1 2025, and up 508.54% quarter-over-quarter from -$445000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 220.63% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 125.79% increase from a year earlier, with the FY2025 full-year figure at $535000.0, up 3721.43% from the prior year.
- Change in Account Payables improved to $1.8 million in Q1 2026 per DMAC's latest filing, from -$445000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.8 million in Q1 2026 and bottomed at -$924000.0 in Q2 2023.
- The 5-year median for Change in Account Payables is $43000.0 (2024), against an average of $163764.7.
- Across the five-year window, Change in Account Payables soared 5785.71% in 2024 and sank 672.09% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at -$130000.0 in 2022, then surged by 148.46% to $63000.0 in 2023, then tumbled by 466.67% to -$231000.0 in 2024, then slumped by 92.64% to -$445000.0 in 2025, then soared by 508.54% to $1.8 million in 2026.
- Per Business Quant, the three latest DMAC Change in Account Payables figures stand at $1.8 million (Q1 2026), -$445000.0 (Q4 2025), and $659000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | DiaMedica Therapeutics | 364.72 Mn | 364.72 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | -445,000.00 |
| Dec 31, 2025 | -445,000.00 |
| Sep 30, 2025 | 659,000.00 |
| Sep 30, 2025 | 659,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Mar 31, 2025 | 567,000.00 |
| Mar 31, 2025 | 567,000.00 |
| Dec 31, 2024 | -231,000.00 |
| Dec 31, 2024 | -231,000.00 |
| Sep 30, 2024 | 412,000.00 |
| Sep 30, 2024 | 412,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | -210,000.00 |
| Mar 31, 2024 | -210,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |